title: Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy.
abstract: Inhibiting angiogenesis has become a major therapeutic strategy for cancer treatment. To identify common intracellular mediators, we previously analyzed gene expression profiles of endothelial cells after treatment with angiogenesis inhibitors. Filamin A interacting protein 1-like (FILIP1L; previously known as down-regulated in ovarian cancer 1) was identified as one of the genes up-regulated in endothelial cells in response to these inhibitors. However, the expression and function of FILIP1L protein is uncharacterized. Here, we provide the first description of the expression and specific subcellular localization of FILIP1L protein in human tissue. Overexpression of FILIP1L resulted in inhibition of cell proliferation and migration and increased apoptosis. In addition, overexpression of FILIP1L truncation mutants showed differential antiproliferative activity. A COOH terminal truncation mutant (FILIP1LDeltaC103) was more potent than wild-type FILIP1L in mediating this activity. Targeted expression of FILIP1LDeltaC103 in tumor vasculature inhibited tumor growth in vivo. Overall, these findings suggest that the novel protein FILIP1L may be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potential to be an antivascular reagent for cancer therapy.
authors.affiliation: Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
authors.forename: Mijung
authors.initials: M
authors.lastname: Kwon
authors.forename: Engy
authors.initials: E
authors.lastname: Hanna
authors.forename: Dominique
authors.initials: D
authors.lastname: Lorang
authors.forename: Mei
authors.initials: M
authors.lastname: He
authors.forename: John S
authors.initials: JS
authors.lastname: Quick
authors.forename: Asha
authors.initials: A
authors.lastname: Adem
authors.forename: Christina
authors.initials: C
authors.lastname: Stevenson
authors.forename: Joon-Yong
authors.initials: JY
authors.lastname: Chung
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Hewitt
authors.forename: Enrique
authors.initials: E
authors.lastname: Zudaire
authors.forename: Dominic
authors.initials: D
authors.lastname: Esposito
authors.forename: Frank
authors.initials: F
authors.lastname: Cuttitta
authors.forename: Steven K
authors.initials: SK
authors.lastname: Libutti
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D003110:Colonic Neoplasms / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D016207:Cytokines / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism; D018076:DNA, Complementary / Q000235:genetics; D043169:Endostatins / Q000494:pharmacology; D042783:Endothelial Cells / Q000378:metabolism / Q000473:pathology / Q000502:physiology; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008545:Melanoma / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D013347:Subcellular Fractions / Q000378:metabolism; D014162:Transfection; D015854:Up-Regulation / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D016207:Cytokines; D018076:DNA, Complementary; D043169:Endostatins; C504459:FILIP1L protein, human; D047908:Intracellular Signaling Peptides and Proteins
references.citation: Cancer Res. 2003 Oct 1;63(19):6405-12
references.pmid: 14559830
references.citation: Cancer Sci. 2006 Dec;97(12):1359-65
references.pmid: 16999820
references.citation: Curr Opin Mol Ther. 2004 Feb;6(1):54-70
references.pmid: 15011782
references.citation: Neoplasia. 2005 Sep;7(9):816-23
references.pmid: 16229804
references.citation: Cancer Res. 1998 Aug 15;58(16):3751-6
references.pmid: 9721889
references.citation: Nature. 1993 Dec 9;366(6455):591-2
references.pmid: 8255299
references.citation: Cell. 1997 Jan 24;88(2):277-85
references.pmid: 9008168
references.citation: J Biol Chem. 1994 Oct 7;269(40):25106-19
references.pmid: 7929199
references.citation: J Biol Chem. 2001 May 25;276(21):17871-7
references.pmid: 11278410
references.citation: J Biol Chem. 1992 Oct 5;267(28):20239-47
references.pmid: 1400342
references.citation: Nat Protoc. 2007;2(2):416-23
references.pmid: 17406603
references.citation: Science. 1999 Apr 2;284(5411):147-51
references.pmid: 10102815
references.citation: Biochemistry (Mosc). 2007 Mar;72(3):235-46
references.pmid: 17447877
references.citation: Nat Cell Biol. 2002 Jul;4(7):495-501
references.pmid: 12055638
references.citation: Trends Cardiovasc Med. 2006 Apr;16(3):80-8
references.pmid: 16546688
references.citation: Cancer Metastasis Rev. 1992 Mar;11(1):69-77
references.pmid: 1511498
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):270-80
references.pmid: 18172279
references.citation: J Biol Chem. 2002 Jun 14;277(24):21998-2009
references.pmid: 11909861
references.citation: J Virol. 2006 Feb;80(4):1922-38
references.pmid: 16439548
references.citation: J Immunother. 2000 Sep-Oct;23(5):519-27
references.pmid: 11001545
references.citation: Nat Protoc. 2007;2(3):523-31
references.pmid: 17406616
references.citation: Exp Cell Res. 2005 Dec 10;311(2):229-39
references.pmid: 16248999
references.citation: J Neurosci. 2004 Oct 27;24(43):9648-57
references.pmid: 15509752
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):138-45
references.pmid: 11252955
references.citation: Cytokine. 2005 Jun 21;30(6):347-58
references.pmid: 15935955
references.citation: FEBS Lett. 2000 Dec 15;486(3):247-51
references.pmid: 11119712
references.citation: Nat Cell Biol. 2001 Dec;3(12):1060-8
references.pmid: 11781567
references.citation: Nat Cell Biol. 2007 Jul;9(7):838-46
references.pmid: 17572668
references.citation: J Biol Chem. 2000 Jan 7;275(1):271-8
references.pmid: 10617615
references.citation: J Biol Chem. 2003 Sep 26;278(39):37895-901
references.pmid: 12851410
references.citation: Cell. 2006 Apr 21;125(2):385-98
references.pmid: 16630824
references.citation: Nat Genet. 2003 Apr;33(4):487-91
references.pmid: 12612583
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1554-9
references.pmid: 14747654
references.citation: Nat Cell Biol. 2002 Sep;4(9):681-90
references.pmid: 12198493
references.citation: J Biol Chem. 2002 Apr 26;277(17):14877-83
references.pmid: 11836256
references.citation: Nature. 1990 Dec 6;348(6301):555-7
references.pmid: 1701033
references.citation: Genome Res. 2004 Aug;14(8):1585-93
references.pmid: 15289477
references.citation: Exp Cell Res. 2008 Feb 15;314(4):834-46
references.pmid: 18177638
references.citation: Curr Drug Targets. 2004 Jul;5(5):485-93
references.pmid: 15216914
references.citation: Nat Cell Biol. 2006 Aug;8(8):803-14
references.pmid: 16862148
references.citation: J Biol Chem. 2003 Jan 10;278(2):1328-35
references.pmid: 12376540
references.citation: Neuron. 1998 Dec;21(6):1315-25
references.pmid: 9883725
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6427-32
references.pmid: 10841547
references.citation: J Virol. 2002 Apr;76(7):3395-420
references.pmid: 11884566
references.citation: Cancer Res. 2002 Apr 1;62(7):1944-7
references.pmid: 11929807
references.citation: J Exp Med. 1999 Aug 2;190(3):341-54
references.pmid: 10430623
references.citation: Gynecol Oncol. 1994 Feb;52(2):247-52
references.pmid: 8314147
references.citation: J Cell Sci. 2004 Oct 1;117(Pt 21):5013-22
references.pmid: 15383615
references.citation: Nat Cell Biol. 2000 Dec;2(12):888-92
references.pmid: 11146652
references.citation: Cancer Lett. 2003 Jun 30;196(1):1-12
references.pmid: 12860282